Brought to you by 
Boston Scientific wins $27bn bid for Guidant
12 Nov 2020
Executive Summary
In an effort to top rival Johnson & Johnson's recent $21.5bn offer, Boston Scientific Corp. has made its own cash and stock bid for Guidant. BSC has proposed $72 per share ($36 in cash and $36 in stock) for each Guidant outstanding share, valuing the deal at about $25bn, a 14% premium to J&J's offer. J&J bid $76 per share for the company a year ago and has revised its offer several times, the latest being $63.43 per share.
Deal Industry
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Medical Devices
- Implantable Devices
- Surgical Equipment & Devices
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Boston Scientific wins $27bn bid for Guidant
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice